Again, ES‐MSCs showed a trend toward reducing GFAP immunoreactivity to a higher degree than AF‐MSCs, with this difference reaching significance in the striatum (Fig. 2 Ci).
← all excerpts
Embryonic Stem Cell-Derived Mesenchymal Stem Cells (MSCs) Have a Superior Neuroprotective Capacity Over Fetal MSCs in the Hypoxic-Ischemic Mouse Brain.
1
—
—